ReviewCurrent pharmaceutical design2026
TSIX: A Novel Long Noncoding RNA in Cancer Development and Progression.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Long noncoding RNAs (LncRNAs) represent a group of long noncoding RNA molecules exceeding 200 nt in length and lacking the capacity for protein coding. In recent years, the function and progress of lncRNA have attracted the attention of more and more researchers. Specifically, the long non-coding RNA, TSIX (TSIX transcript, XIST antisense RNA), plays a significant role in ensuring random X-chromosome inactivation. Recent investigations have highlighted the involvement of lncRNA TSIX in the development of various cancers, emphasizing its crucial functions in tumorigenesis. TSIX has emerged as a novel cancerassociated lncRNA and it is identified for its aberrant expression in diverse tumors, such as those of the breast, gastric, hepatocellular, head and neck, lung, esophageal squamous cell, and uterine smooth muscle. Furthermore, lncRNA TSIX regulates mRNA expression by binding to specific miRNAs, utilizing a competitive endogenous RNA regulatory mechanism. This interaction significantly influences tumor cell proliferation, migration, invasion, and apoptosis. LncRNA TSIX may serve as a useful biomarker or a prospective therapeutic target in a variety of malignant cancers because of the biological functions and mechanisms associated with it.
Indexed as
Identifiers
40574367What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.